Log In Get Started
Press Releases May 27, 2026 07:00 AM

LeonaBio to Participate in Upcoming Medical and Industry Meetings in June

LeonaBio to Present at Key June Medical Meetings Highlighting ALS and Oncology Drug Development

By Priya Menon LONA

LeonaBio, a clinical-stage biopharmaceutical company, announced its participation in two major medical industry events in June 2026. The company will present details on its ALS drug candidate ATH-1105 at the 5th Annual ALS Drug Development Summit and participate in a panel on oncology trials at the BIO International Convention. These engagements underscore LeonaBio's focus on developing treatments for diseases with high unmet needs like ALS and metastatic breast cancer.

LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
LONA

Key Points

  • LeonaBio will present on ATH-1105's strategic trial design and biomarker integration at the ALS Drug Development Summit.
  • The company will participate in a panel discussing the future of oncology trials at the BIO International Convention.
  • LeonaBio focuses on novel therapeutics for treatment-resistant metastatic breast cancer and ALS, addressing unmet medical needs.

BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it will participate in the 5th Annual ALS Drug Development Summit, taking place June 2-4, 2026 in Boston, MA, and the BIO International Convention, taking place June 22-25, 2026 in San Diego, CA.

Details are as follows:

5th Annual ALS Drug Development Summit

Oral Presentation Title: Advancing ATH-1105 in ALS: Strategic Trial Design, Biomarker Integration & Adaptive Methodologies
Session Title: Redefining Biomarkers and Trial Design to Accelerate Neurodegenerative Disease Therapies
Presenter: Javier San Martin, M.D., Chief Medical Officer, LeonaBio
Presentation Date and Time: Wednesday, June 3, 2026, at 2:50 p.m. ET
Location: The Colonnade Hotel, Boston, MA

BIO International Convention

Panel Presentation Title: The Future of Oncology Trials: Aligning Science, Regulation, and Investment in Overall Survival
Presenter: David Portman, M.D., Chief Executive Officer, Sermonix; Oncology Consultant, LeonaBio
Panel Date and Time: Wednesday, June 24, 2026, at 11:00 a.m. PT
Location: Room 32AB, San Diego Convention Center, San Diego, CA

About LeonaBio
LeonaBio, headquartered in the Seattle, Washington area, is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patients’ lives. Our lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. With a strong commitment to scientific excellence and patient-centered innovation, we are dedicated to developing meaningful new therapies for those who need them most.

For more information, visit www.leonabio.com.

Investor & Media Contact:
Julie Rathbun
LeonaBio
[email protected]
206-769-9219


Risks

  • Clinical trial outcomes for ATH-1105 are uncertain and could affect development progress.
  • Regulatory challenges in advancing novel therapies for neurodegenerative diseases and oncology may delay product approvals.
  • Market adoption risks exist due to competition and efficacy compared to existing or future treatments.

More from Press Releases

Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026 SOLV Energy Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock Jun 4, 2026 NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option Jun 4, 2026